Converse All Star 2 White
GenSpera to Present at Rodman Renshaw 16th Annual Global Investment Conference
Information contained on this page is provided by an independent third party content provider. WorldNow and this Station make no warranties or representations in connection therewith.CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G 202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street AudienceSAN ANTONIO, Aug. 14, 2014 /PRNewswire/ GenSpera, Inc. Converse All Star 2 White (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman Renshaw 16th Annual Global Investment Conference. The conference will be held September 8 10, 2014 at the New York Palace Hotel in New York.The conference is attended by public companies, institutional investors, sophisticated private investors and industry executives.GenSpera will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss the significance of the recently announced HCC clinical trial update for G 202, its lead drug candidate, as well as provide a corporate overview. The company has released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib ( Nexavar, a drug co developed and co marketed by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary). Impressively, 80% of patients treated with G 202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study. In addition, imaging analysis demonstrated impressive blockade of tumor blood flow in the single patient evaluated by this method to date.Hepatocellular carcinoma (HCC) is currently the sixth most common malignancy in the world and the third leading cause of cancer related mortality worldwide.Craig Dionne, PhD, GenSpera CEO said of the pending conference," I am excited to share the recent data and results for G 202 and its efficacy and safety analyses on patients to date. G 202 has potential to treat multiple cancers including prostate cancer and glioblastoma but our primary focus is currently hepatocellular carcinoma (HCC). The liver cancer data we recently presented at APPLE and other scientific conferences was overwhelmingly embraced by our peers; now this conference creates an opportunity to explain the significance and the promise it holds to the investment community."GenSpera technology platform combines a powerful, plant derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast Converse Trainers Sale Size 7
almost all other solid tumors. G 202 is therefore expected to have potential efficacy in a wide variety of tumor types.G 202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.This news release may contain forward looking statements. Ladies Converse Uk Sale
and slow growing cancers. GenSpera lead drug candidate, G 202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of Buy Converse Shoes Sale
Investors are cautioned that statements in this press release regarding potential applications of GenSpera technologies constitute forward looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward looking statements.
Converse All Star 2 White
Lv Belts Replica